DURHAM, N.C., and BEIJING, China – October 28, 2022  Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced its participation in the following conferences in November 2022. Details of the conferences and management presentations are as follows:

Citi China Investor Conference 2022

Investor Meetings: November 1-4, 2022
Participants: Management team and IR
For more information, please contact your Citi representative.

Goldman Sachs Asia Pacific Healthcare Forum 2022

Investor Meetings: November 15-18, 2022
Participants: Management team and IR
For more information, please contact your Goldman Sachs representative.

About Brii Bio

Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens worldwide. For more information, visit www.briibio.com.

Media Inquiry:
media@briibio.com
Darcie Robinson
+1-203-919-7905

Investor Inquiry:
ir@briibio.com